Caribou Biosciences, Inc. (CRBU)
Largest Insider Buys in Sector
CRBU Stock Price History Chart
CRBU Stock Performance
About Caribou Biosciences, Inc.
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The …
Insider Activity of Caribou Biosciences, Inc.
Over the last 12 months, insiders at Caribou Biosciences, Inc. have bought $0 and sold $0 worth of Caribou Biosciences, Inc. stock.
On average, over the past 5 years, insiders at Caribou Biosciences, Inc. have bought $149,671 and sold $314,343 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 7,387 shares for transaction amount of $29,553 was made by Fischesser Ryan (VP of Finance and Controller) on 2022‑01‑11.
List of Insider Buy and Sell Transactions, Caribou Biosciences, Inc.
| 2023-01-19 | Sale | Chief Medical Officer | 5,627 0.0093% | $6.31 | $35,506 | -16.06% | ||
| 2022-10-06 | Sale | VP of Finance and Controller | 10,000 0.0162% | $10.80 | $107,958 | -43.36% | ||
| 2022-08-25 | Sale | Chief Scientific Officer | 43,248 0.0707% | $11.22 | $485,221 | -41.04% | ||
| 2022-01-11 | VP of Finance and Controller | 7,387 0.0038% | $4.00 | $29,553 | -29.34% | |||
| 2021-12-20 | VP of Finance and Controller | 1,136 0.0003% | $2.69 | $3,056 | -38.62% | |||
| 2021-12-07 | Chief Legal Officer | 6,127 0.0015% | $2.69 | $16,482 | -50.11% | |||
| 2021-10-20 | Chief Legal Officer | 9,219 0.0021% | $2.69 | $24,799 | -50.25% | |||
| 2021-10-12 | Chief Scientific Officer | 114,860 0.0179% | $1.92 | $220,757 | -51.66% | |||
| 2021-10-11 | VP of Finance and Controller | 1,746 0.0004% | $2.69 | $4,697 | -48.53% |
Insider Historical Profitability
| MCCLUNG BARBARA G | Chief Legal Officer | 348971 0.3862% | $2.74 | 2 | 0 | <0.0001% |
| Kanner Steven | Chief Scientific Officer | 302059 0.3343% | $2.74 | 1 | 1 | <0.0001% |
| Fischesser Ryan | VP of Finance and Controller | 110366 0.1221% | $2.74 | 3 | 1 | <0.0001% |
Institutional Investor Ownership
| BlackRock | $36.01M | 7.76 | 7.01M | -0.9% | -$325,906.84 | <0.01 | |
| PFM Health Sciences | $33.32M | 7.18 | 6.48M | +0.04% | +$12,880.84 | 0.92 | |
| State Street | $32.63M | 7.03 | 6.35M | +23.98% | +$6.31M | <0.01 | |
| Avidity Partners Management Lp | $29.74M | 6.41 | 5.79M | -9.04% | -$2.95M | 1.13 | |
| The Vanguard Group | $21.13M | 4.55 | 4.11M | +3.75% | +$764,580.13 | <0.0001 |